Annate Bitherapeutics

DEVELOPING THE NEXT GENERATION THERAPY FOR MULTIPLE MYELOMA

TARGETING THE HUMAN

INNATE IMMUNE SYSTEM

ANNATE BITHERAPEUTICS

Annate is a Private, Pre-Clinical Stage Biotechnology Company

Multiple Myeloma

Plasma cell malignancy

- **High Relapse Rate:**
  - >85% MM patients **relapse** and develop **resistance**
  - 1% of cancers, 10% blood cancers
- **Triple-class relapsed/refractory MM:**
  - patients whose cancer has progressed despite treatment with all three main drug classes
  - Low Overall Survival: 9-18 months
  - These patients need new options
- **Emerging therapies in development**
  - CAR T
  - BiTEs
  - ADCs



Frontiers | Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers

Despite advances in treatment,

Multiple Myeloma is still incurable

Our Ground-breaking Approach: Redirecting Apolipoprotein L1

Apolipoprotein L1 (**ApoL1**) **is a naturally occurring** component of the human innate immune system.

ApoL1 is found within human HDL complexes

Evolved as **cytotoxic** defense against African trypanosomes (parasite)



We Asked: Can we use this to kill cancer?

ANN-01M – Our Next Generation Therapeutic

1) The therapeutic - **ANN-01M** - is a bispecific antibody that is directly injected into the patient.
2) ANN-01M then binds **freely circulating** ApoL1 in your bloodstream
3) ANN-01M brings ApoL1 specifically to Multiple Myeloma cells
4) ANN-01M is internalized along with its toxic ApoL1 payload



Reprogramming Nature's Immune Weapon To Kill Cancer

ANN-01M – Our Next Generation Therapeutic

1) The therapeutic - **ANN-01M** - is a bispecific antibody that is directly injected into the patient.
2) ANN-01M then binds **freely circulating** ApoL1 in your bloodstream
3) ANN-01M brings ApoL1 specifically to Multiple Myeloma cells
4) ANN-01M is internalized along with its toxic ApoL1 payload
5) ApoL1 internal activity leads to a cascade of events leading to cell death



Reprogramming Nature's Immune Weapon To Kill Cancer

We *can* selectively target and kill cancer

Key Features of Technology

Active in cells? *Yes*

- Target specific (Safe)
  - No off-target toxicity
- **Significant** cell death (Effective)
  - Single dose bsAb
  - Physiologic ApoL1 levels





We *can* selectively target and kill cancer

Key Features of Technology

Active in animals? *Yes*

- Preliminary study with ANN-01M prototype
  - Decreased tumor growth >45%
  - Decreased tumor burden >40%
- Developing Improvements
  - Prototype bsAb with room for optimization
  - Lowest dose possible, room to grow
  - No GSI inhibitor yet, which reliably increases toxicity ~50%
  - Observed response equivalent with stage of development of approved drugs





From Urgent Need to Early Intervention

Total US Market

140k patients

$28B

If safety proves out, advance to Newly RRMM and Smoldering MM

~75,000 patients

$13B

First targeted group: Triple Class Refractory

~5,500 patients

$1.5B

ANNATE BITHERAPEUTICS

Competitive Analysis

Feature	ANN-01M	CAR-T Cell Therapy	T-Cell Engagers (BiTEs)	Antibody–Drug Conjugates (ADCs)	Monoclonal Antibodies (CD38 / SLAMF7)
Immune Cell Requirement	✅ Immune-cell independent	❌ Requires T cells	❌ Requires T cells	⚠️ ADCC dependent	⚠️ NK/ADCC dependent
Cytotoxic Payload	✅ None (ApoL1 selective)	✅ None	✅ None	❌ Chemotoxic payload	✅ None
Manufacturing	✅ Off-the-shelf	❌ Personalized	⚠️ Limited by T cells	✅ Off-the-shelf	✅ Off-the-shelf
Mechanism of Action	✅ Novel lysosomal disruption	T-cell cytotoxicity	T-cell engagement	Payload-dependent	Immune-mediated
Toxicity Profile	✅ Low toxicity	❌ CRS / ICANS	❌ CRS / ICANS	❌ Possible/Systemic	⚠️ Cytopenias

ANNATE BITHERAPEUTICS

Strong and Experienced Team

Eric DeJesus, PhD.
Founder and CEO

Michael Cipriano, PhD.
Founder and Vice President

Stephen Hajduk, PhD.
Founder and CSO

Strategic Advisors

Brian Longstreet
Exolvo Biosciences
Ex: Merck & Schering-Plough

Martin Moore, PhD.
Ollabio Inc.
Ex: Meissa Vaccines

Ajay Nooka, MD MPH
Winship Cancer Institute of Emory

Clinical Advisors

Greg Lesinski, PhD MPH
Winship Cancer Institute of Emory

Vikas Gupta, MD PhD
Winship Cancer Institute of Emory

Mohammad Zaidi, MD
Winship Cancer Institute of Emory

ANNATE BITHERAPEUTICS

Our Ask:
Drive to Inflection

- **Raising $1.5M through a SAFE**
  - $18M valuation cap
  - Friends & Family: >$400k committed
- **Pre-Seed proceeds support**
  - pre-GLP efficacy
  - PK/PD
  - MOA validation



ANNATE BITHERAPEUTICS

High-Level Key Target and $1.5M Funding Plan

Key Objectives & Funding Horizon



* This represents a **conservative** plan. Targeted accelerations are possible with manageable risk.

Annate Bitherapeutics

Developing New Possibilities

www.AnnateBitherapeutics.com

Next Generation Therapeutic for Multiple Myeloma

Novel Mechanism of Action: *immune cell independent*

Proven delivery system: *bispecific antibody*



UGARF owns IP: Annate holds Option to Exclusive License

High Versatility Approach

Up to 5 malignancies with our primary lead alone

Can successfully target *other* biomarkers with efficacy

Liquid *and* solid tumors targetable